Autoimmune joint destruction could become far more manageable with precision molecular tools that target inflammatory proteins exactly where disease occurs, rather than suppressing immunity throughout the entire body. This breakthrough addresses a fundamental challenge in treating rheumatoid arthritis without compromising the patient's ability to fight infections or cancer. Researchers engineered charge-switching polymers that specifically seek out inflamed joint tissue and degrade STING, a key inflammatory signaling protein driving rheumatoid arthritis progression. These smart materials remain inactive in healthy tissue but activate their protein-degrading function only within the acidic, enzyme-rich environment of arthritic joints. The polymers demonstrated selective STING elimination in diseased joints while preserving normal immune function elsewhere in laboratory models. Unlike conventional immunosuppressive drugs that broadly dampen immune responses system-wide, this targeted approach degrades the problematic protein exclusively at sites of inflammation. The charge-reversal mechanism ensures the therapeutic payload activates only under specific pathological conditions found in inflamed synovial tissue. This represents a significant advance over current rheumatoid arthritis treatments, which often leave patients vulnerable to opportunistic infections and malignancies due to generalized immune suppression. The tissue-specific degradation strategy could transform autoimmune disease management by providing potent anti-inflammatory effects without systemic immunocompromise. However, translation to human patients will require extensive safety testing to confirm the polymers maintain their tissue selectivity across diverse physiological conditions. The approach may prove applicable to other localized inflammatory conditions where targeted protein degradation could provide therapeutic benefit without systemic side effects.